The global companion diagnostic tests in oncology market is witnessing robust growth, driven by the rising demand for personalized cancer treatment and rapid advancements in diagnostic technologies. Valued at US$ 6.1 billion in 2023, the market is projected to reach US$ 17.0 billion by 2034, expanding at a compound annual growth rate (CAGR) of 9.5% during the forecast period. Role of Companion...